Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart

scientific article published on 01 August 2000

Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1003723558
P356DOI10.1007/S002280000159
P698PubMed publication ID11009049

P2093author name stringA Riis
L V Jacobsen
B Søgaard
P433issue5
P921main subjectpharmacokineticsQ323936
pharmacodynamicsQ725307
P304page(s)399-403
P577publication date2000-08-01
P1433published inEuropean Journal of Clinical PharmacologyQ1376707
P1476titlePharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart
P478volume56

Reverse relations

cites work (P2860)
Q44746359Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy
Q34620736Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
Q42014274Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy
Q46066342Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes
Q36798592Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review
Q34707605Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study
Q33603569Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30.
Q44655654Comparison of thrice daily ‘high’ vs. ‘medium’ premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes
Q61805812Efficacy Comparison of Preprandial and Postprandial Prandilin 25 Administration in Patients with Newly Diagnosed Type 2 Diabetes Using a Continuous Glucose Monitoring System
Q51450846Efficacy and safety of biphasic insulin aspart 30/70 in the treatment of patients with type 2 diabetes mellitus.
Q37292166Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results.
Q42241823Initiating or switching to biphasic insulin aspart 30/70 therapy in subjects with type 2 diabetes mellitus. An observational study.
Q34820360Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus
Q34365284Insulins today and beyond
Q37577153Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?
Q35149357Limitations to subcutaneous insulin administration in type 1 diabetes
Q35087356New aspects of insulin therapy in type 1 and type 2 diabetes
Q46883811Premixed insulin analogues for the treatment of diabetes mellitus
Q37058917Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
Q37250601Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
Q51275520TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES.
Q38028009Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings
Q37718811Treatment adherence in patients with type 2 diabetes mellitus correlates with different coping styles, low perception of self-influence on disease, and depressive symptoms
Q44655656Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes
Q43997770Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus
Q40304141Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling.

Search more.